Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2025; 31(48): 114786
Published online Dec 28, 2025. doi: 10.3748/wjg.v31.i48.114786
Published online Dec 28, 2025. doi: 10.3748/wjg.v31.i48.114786
Harnessing early enzymatic biomarkers and cytokines for risk prediction in post-endoscopic retrograde cholangiopancreatography pancreatitis
Abdellatif Bouayad, Laboratory of Immunology, Mohammed First University, Faculty of Medicine and Pharmacy Oujda, Oujda-Angad 4867, Oriental, Morocco
Author contributions: Bouayad A wrote and designed the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abdellatif Bouayad, MD, Associate Professor, Laboratory of Immunology, Mohammed First University, Faculty of Medicine and Pharmacy Oujda, 4867 Oujda l’Université, Oujda-Angad 4867, Oriental, Morocco. a.bouayad@ump.ac.ma
Received: September 27, 2025
Revised: October 28, 2025
Accepted: November 12, 2025
Published online: December 28, 2025
Processing time: 90 Days and 8.6 Hours
Revised: October 28, 2025
Accepted: November 12, 2025
Published online: December 28, 2025
Processing time: 90 Days and 8.6 Hours
Core Tip
Core Tip: Although high serum 4-hour amylase and lipase levels enable early diagnosis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, they have limited prognostic value and lack etiological specificity. Interleukin (IL)-6 has emerged as an early inflammatory biomarker for predicting post-ERCP pancreatitis severity. However, detection and quantification of this cytokine remain costly. Validation of rapid, cost-effective, and point-of-care IL-6 immunoassays is essential for their inte